SplitMay 11, 2026, 10:02 AM
Revelation Biosciences Seeks Reverse Stock Split Authority
AI Summary
Revelation Biosciences, Inc. announced its 2026 Annual Meeting of Stockholders, to be held virtually on June 24, 2026. A key proposal includes granting the board discretionary authority to implement a reverse stock split at a ratio between 1-for-2 and 1-for-250 within one year, primarily to maintain Nasdaq listing compliance. The company has previously conducted multiple reverse stock splits in 2025 and 2026 to address minimum bid price requirements. Additionally, stockholders will vote on the election of a Class A director and the ratification of Baker Tilly US, LLP as the independent auditor for fiscal year 2026.
Key Highlights
- Annual Meeting of Stockholders scheduled for June 24, 2026, held virtually.
- Board seeks authority for a reverse stock split ratio of 1-for-2 to 1-for-250.
- Company executed a 1-for-16 reverse stock split on January 28, 2025.
- Company executed a 1-for-3 reverse stock split on July 7, 2025.
- Company executed a 1-for-4 reverse stock split on January 28, 2026.
- Stockholders to elect Jennifer Carver as Class A director until 2029.
- Stockholders to ratify Baker Tilly US, LLP as independent auditor for FY 2026.
- Record date for voting at the Annual Meeting was April 30, 2026.